



EXPLORING THE POTENTIAL OF NANOTECHNOLOGY IN DRUG DELIVERY SYSTEMS

Nawar Dohair Al Joaid, Sultan Saadi Almutairi, Ayed Khaled Alashjaee, Bader Senhat Alotaibi, Bader Hamed Alharthi, Abdulmajeed Abdullah Alothman, Ahmed Ali Harshan, Mohammad Abdulrahman Alzaiber, Fahad Safar Alotaibi, Abdulrahman Falah Mohmmmed Alharbi, Bdulrahman Ibrahim Mohammed Alhaidari, Sarah Bhni Alhali, Zaid Obeed Mobark Aldawsari, Hazal Saud Kaud Alotaby, Talal Hamoud Abdullah Al-osaimi

Abstract:

Nanotechnology has emerged as a transformative force in healthcare, particularly in the realm of drug delivery systems. The ability to engineer nanoparticles with precise size, shape, and surface properties has revolutionized the administration of therapeutic agents. This advancement addresses longstanding challenges in conventional drug delivery, such as poor solubility, limited bioavailability, and off-target effects. By harnessing the unique properties of nanomaterials, researchers have developed novel strategies to enhance drug efficacy while minimizing toxicity. Size and shape considerations are paramount in nanotechnology-based drug delivery, influencing cellular uptake, biodistribution, and pharmacokinetics. Moreover, surface characteristics play a crucial role in modulating nanoparticle interactions with biological molecules and tissues. Through meticulous design and engineering, nanocarriers can be tailored to target specific tissues or cells, offering unprecedented precision in drug delivery. Despite its immense potential, nanotechnology also presents challenges, including concerns about toxicity and regulatory oversight. Addressing these issues requires comprehensive research in nanotoxicology and robust regulatory frameworks. However, the promise of nanotechnology in revolutionizing personalized medicine and improving patient outcomes is undeniable. With ongoing advancements in nanomaterial synthesis, formulation techniques, and targeted delivery strategies, the future of nanotechnology-based drug delivery systems holds immense promise for transforming healthcare.

Introduction:

The word "nanotechnology" was first used in 1974 by Tokyo University engineer Norio Taniguchi. Twenty-nine years later, the word became popular once more, and it is currently used to describe the development of materials and systems that have dimensions or manufacturing constraints lower than 100 nanometers (nm). Nevertheless, this 100 nm limit is arbitrary and changes based on the particular need. For example, any size smaller than a micrometer is referred to as nanometric in the medical industry. This scale makes it possible to precisely regulate how drugs are distributed throughout the body and how implants and tissues interact.



All the articles published by Chelonian Conservation and Biology are licensed under a [Creative Commons Attribution-NonCommercial4.0 International License](https://creativecommons.org/licenses/by-nc/4.0/) Based on a work at <https://www.acgpublishing.com/>

Over the past ten years, interest in nanotechnology has grown in several scientific fields. The arrangement of atoms and electrons within a range of nanometers gives compounds their distinct characteristics at the nanoscale. Prior to the formalization of nanotechnology, a number of techniques and procedures made use of substances that were somewhat crude, such as silica, carbon black, titanium dioxide, and zinc oxide. Nowadays, nanotechnology is a well-developed field [1].

Drugs, cosmetics, nutraceuticals, and therapeutic agents are examples of products generated by nanotechnology. While they may not always display quantum behavior, they can interact with biological molecules in ways that are remarkable when contrasted to their larger counterparts. Because nanosystems may be directly targeted to particular areas within the body, they offer advantages over traditional delivery systems. Nanomedicine is one prominent use of nanotechnology. Applications of nanotechnology, such as nanomedicine, are critical to many facets of healthcare, including illness prevention, treatment, diagnosis, and monitoring. Its wide range of uses includes targeted medicines, in vivo imaging, antimicrobial medical fabrics, nanoscale drug delivery, and sophisticated biomarker detection. Biomarkers can be more precisely identified and comprehended by utilizing nanotechnology, which will help with insulin delivery, tissue regeneration, blood glucose monitoring, and disease staging. For example, image-guided neurostimulator implantation improves treatment delivery precision, and three-dimensional nanomaterials can immobilize stem cells at damage sites. More developments in nanomedicine could lead to targeted, regenerative, and patient-specific medical technologies, opening up new possibilities for individualized treatment [2].

But as technology advances, new responsibilities also arise. It is therefore critical to evaluate the possible effects of nanoproducts at every stage of their lifecycle, from manufacture and use to disposal. Concerns about health and the environment are raised because of the potential harm that nanoproducts may cause. Inhaling carbon black and titanium dioxide nanoparticles, for example, may result in reduced sperm count, carcinogenic consequences, inflammation, and increased risks of diseases mediated by oxidative stress. These difficulties highlight how crucial it is to carefully consider and control the uses of nanotechnology in order to guarantee its safe and advantageous incorporation into medical procedures [3].

Diagnosis applications in nanomedicine involve in vitro tests utilizing sensors to detect molecules indicative of specific diseases, known as biomarkers. For instance, DNA-coated gold nanoparticles combined with biosensor chips facilitate the detection of hereditary diseases by measuring protein values. In vivo measurements of biomarkers are conducted using imaging techniques, with nanoparticles serving as contrast agents. This enables visualization of small tumors through magnetic resonance tomography, utilizing magnetic iron oxide nanoparticles attached to supports. Diagnostic tests, such as the "Lab-on-a-chip," offer streamlined diagnostic capabilities, including the monitoring of potassium levels in blood from home settings.

Therapeutic applications of nanomedicine encompass both passive and active drug release mechanisms. Passive drug release involves therapeutic drugs encapsulated within hollow nanostructures, such as liposomes, which target tumors. Active drug release employs nanocapsules equipped with molecular antennas, releasing their contents upon contact with specific disease structures. Nanoparticles also play a role in thermotherapy, where they accumulate in tumor blood vessels and are activated by physical components like sound, light, or magnetic waves, generating heat to destroy tumor cells. Tissue regeneration in nanomedicine involves the use of nanoscale biomaterials to facilitate tissue repair and growth. Biomaterial matrices containing peptides, nanofibers, and other nano-based materials provide scaffolds for cell proliferation and tissue formation. Additionally, tissue regeneration through cell therapy entails culturing cells outside the body and then using them to support self-healing processes. These advancements hold promise for addressing various medical challenges, ranging from diagnostics to therapeutics and tissue repair, through the innovative application of nanotechnology in healthcare.

In conclusion, the introduction provides a comprehensive overview of the evolution and current landscape of nanotechnology, highlighting its origins, applications, and implications in healthcare. Initially coined in 1974 by Norio Taniguchi, the term "nanotechnology" has since become synonymous with the development of materials and systems on the nanoscale, with dimensions below 100 nanometers. This scale offers unprecedented control over drug distribution and tissue interactions, revolutionizing fields like medicine and diagnostics. The surge of interest in nanotechnology over the past decade underscores its potential across various scientific disciplines. From the arrangement of atoms to the development of sophisticated nanosystems, nanotechnology has evolved from crude practices to a mature discipline with diverse applications in drug delivery, diagnostics, and tissue engineering. Nanomedicine, in particular, emerges as a critical application of nanotechnology, offering targeted therapies, precise diagnostics, and innovative tissue regeneration techniques. Through the utilization of nanoscale biomaterials and advanced imaging techniques, nanomedicine holds promise for personalized and regenerative medical technologies. However, alongside technological advancements come new responsibilities, necessitating careful evaluation of the potential health and environmental impacts of nanoproducts. Addressing concerns about safety and sustainability is paramount to ensuring the ethical and beneficial integration of nanotechnology into healthcare practices.

Drug Delivery:

Regardless of the route or mode of drug administration, getting the drug to the intended place is an essential step in the pharmaceutical administration process. Particles with sizes between one and several hundred nanometers are known as nanoparticles, and they are essential to this process. Due to the laws of quantum mechanics, the macroscopic physical properties of nanoparticles change significantly as they get smaller. Particles can change in color, transparency, hardness, and magnetic and electrical characteristics below 50 nm. For instance,

the hue of quantum dots varies with their size. Furthermore, when nanoparticle mass increases, so does their surface area, which affects physical properties like melting and boiling points. Compared to traditional drug delivery methods, nanoparticles provide advantages because of their small size, which allows them to readily pass through biological barriers and enter the body [4].

Four essential conditions must be satisfied for effective drug delivery to the target site: keeping drug-carrying vehicles in the system, avoiding the immune system, getting to the target, and releasing the drug. Medications administered intravenously must be loaded into delivery vehicles in a way that allows the medications to accumulate and settle at the intended location while maintaining their unique properties and guaranteeing the drugs release on schedule. Various drug delivery systems are needed depending on the target site and mode of administration [5].

There are two types of drug targeting: passive and active. Creating a medication and carrier complex for passive targeting entails avoiding removal from the body and facilitating circulation to the target site and target absorption. This frequently makes use of the increased permeability and retention effect, which occurs when medications build up at sick locations. On the other hand, active targeting entails binding the drug-carrier combination to a particular marker, like an antibody or receptor, in order to effectively direct it to a specific target. This depends on certain interactions that occur between the target cells or tissues and the medication delivery vehicle. Drugs can easily and effectively accumulate at specified target areas thanks to these targeting mechanisms [6].

There are two main ways to target drug delivery: intracellular and systemic targeting. When using systemic targeting, the drug-carrier complex enters the targeted region through extravasation through vessel walls and circulation. Locally triggered drug delivery and ligand-receptor-mediated drug delivery are further classifications for this technique. In order to enable precise site targeting, the drug-carrier complex is connected to a ligand or receptor through a process known as ligand-receptor-mediated targeting. Conversely, external activation of drug release from its carrier or self-triggering mechanisms triggered by signals emitted at the target location are necessary for locally activated drug delivery. One type of self-triggered targeting called passive targeting depends on the body's enzymes or pH variations, as well as external stimuli like light, ultrasonic waves, temperature, or electromagnetic fields [7].

Successful drug release in intracellular targeting depends on the drug-carrier combination being delivered directly to the target spot, specifically inside the cell. In order to accomplish this, carriers or vehicles must reach the cytoplasm of the cell and release the medication at a rate that maximizes therapeutic efficacy. It is crucial to comprehend the workings and functions of intracellular trafficking and localization in order to design drug delivery systems that are specifically suited for target delivery. Several approaches and techniques have been used in several research to look into the mechanics of intracellular trafficking. Comprehending these

systems facilitates the development of drug carriers that can be efficiently targeted within the cytoplasm of cells. Delivering drugs is severely hampered by biological barriers, such as epithelia in the lungs, intestinal system, and skin. Both single- and multi-layered epithelia have various molecular transport systems. Hydrophilic materials can travel between neighboring epithelial cells via paracellular transport, whereas small, lipid- and water-soluble molecules can move between cells by transcellular transport. In paracellular transport, tight junctions between cells are essential because they increase the permeability of the cell cluster to tiny molecules. Additionally, ATP binding cassette (ABC) transporters can be involved in active transportation through ATP consumption. Endocytosis is the process by which large molecules enter cells; vesicles carry them across the epithelial barrier. P-glycoprotein and other efflux systems are involved in the transport of molecules over epithelial barriers. Specifically, nanoparticles are able to bind to the apical membrane of epithelial cells, allowing for internalization and subsequent transit across the cell [8]

Since oral administration is convenient and generally accepted by patients, oral bioavailability of medications is important for efficient drug delivery. Unfortunately, the gastrointestinal tract's enzymatic reactions reduce the bioavailability of many oral medications. Drugs can be encapsulated in nanoparticles to get around this barrier and increase the pace at which they are transported through the intestinal mucous membranes. To make drug-encapsulated nanoparticles, biodegradable polymers like guar gum, Xanthan gum, and poly(lactic-co-glycolic acid) (PLGA) are frequently utilized. The gastrointestinal tract dwell time, surface characteristics, and particle size are some of the variables that affect a nanoparticle's transport capabilities. Orally administered gold nanoparticles of varying sizes were dispersed differentially in the bodies of mice, according to studies by Hillyer and Albrecht. Smaller particles were identified in the bloodstream, whereas larger particles accumulated in organs such as the stomach, intestines, and kidneys [9].

Cellular transport is further improved by surface-modified nanoparticles coated with bioadhesive substances such as polyethylene glycol (PEG), polyvinyl alcohol (PVA), or vitamin E-d-alpha-tocopheryl PEG succinate. These coatings increase adherence to cells and may have an impact on ABC transporters that are part of the efflux system, which could lengthen the time that nanoparticles remain inside of cells. Glycotargeting, a fascinating method of drug targeting involving the use of lectins and neo-glycoconjugates to target the colon, is another interesting strategy. This strategy can work in one of two ways: either specific lectins interact with sugar molecules on cell surfaces to facilitate active substance transport, or oligosaccharides or neo-glycoconjugates function as a component of the active transport system, binding to cell surface lectins and undergoing endocytosis. Glycotargeting presents new opportunities for targeted drug therapy in gastrointestinal illnesses by providing the possibility of precise drug delivery to the colon [10].

Fundamentals of Nanotechnology for Drug Delivery:

Changes in nanoparticle size, content, and driving technologies are all part of the continually changing field of nanotechnology research. This section explores basic ideas that are essential to comprehend materials and how they interact with living molecules. In the context of drug delivery, getting over a variety of obstacles—including those related to particle size, shape, charge, and interactions with cell membranes—is necessary to achieve target cell internalization. Drug delivery vehicles' dimensions and forms are crucial for precisely locating and administering medications to target locations, especially in tiny blood vasculature and clogged tumor vascular networks. These elements also affect how cells behave and react to particles that they want to internalize. They also change the particle's surface-to-volume ratio, which affects drug vehicle elimination, metabolism, and plasma dynamics. After entering circulation, carriers have to pass through vessel walls in order to target specific targets and apply their effects. The size of nanoparticles influences circulation clearance, blood concentration, diffusion through vessels, and biodistribution, which makes it easier for biomacromolecules to enter drug delivery vehicles with comparable dimensions [11].

Many nanoparticle-based vehicles have been chemically manufactured in the last few decades, mostly by top-down methods. Examples of nanoparticle drug carriers that have shown promise and sparked considerable interest include liposomal nanocarriers, solid polymeric nanoparticles, micellar formulations, and polymer-drug conjugates. Top-down methods that use fabrication techniques based on nano- and micro-electromechanical systems have become more popular recently. These methods allow for the production of homogenous nano- and micro-drug carriers with the appropriate size and shape. Compared to conventional top-down techniques, top-down procedures have the advantage of simpler control over particle size and shape—a characteristic that is frequently difficult to maintain [12-13].

When it comes to nanotherapeutics, size and shape are important factors that have a big impact on how well drugs are delivered. Drug components with nanoscale structure, like nanocrystals, are engineered to improve solvation rates, whereas loaded nanotherapeutics are made to maximize other beneficial features including plasma kinetics. The importance of particle size in affecting target cells' ability to phagocytose drug-loaded poly(lactic-co-glycolic) acid microspheres (PLGA-MS) is highlighted by research conducted by Liu et al. (2016) [14].

Studies on the size of nanoparticles raise questions about subtle interactions in the body. More than 5 μm nanoparticles are often caught in the capillary bed of organs such as the liver, where they are consumed by Kupffer cells. On the other hand, nanodrug carriers larger than 200 nm and smaller than 1 μm easily penetrate the spleen, whereas those between 1 μm and 5 μm concentrate at liver target sites. Particles smaller than 100 nm, however, get stuck in the blood vessel endothelium linings' pores. Smaller than 200 nm polystyrene nanoparticles show improved resistance to identification by the macrophage system, extending their half-life in circulation and enabling target delivery. Further difficulties arise from hemodynamic forces in the blood, especially for spherical particles. These forces are amplified by increased particle diameter, which makes external interactions like van der Waals or electrostatic forces necessary

for circulation. Random forces cause nonspherical nanodrug carriers to unbalance, roll, or tumble during blood circulation; particle behavior is determined by the form of the carrier. For example, the geometry of cuboidal nanoparticles makes them more vulnerable to blood flow pressure, ellipsoidal particles wander sideways, and filamentous polymer micelles show longer blood flow persistence than their spherical counterparts [15].

It is possible to modify the critical distance of bonds retaining atoms to modify the hardness or softness of nanomaterials. Due to limited bond displacement, small-sized polycrystalline materials can display hardness, but others may become softer as a result of fewer interatomic bonds. Surface forces and body forces are the two forms of energy that particles have. Surface molecules exert surface forces, whereas all molecules within particles contribute to body forces. Surface forces rise with decreasing size, greatly affecting the characteristics of the material. Particle attraction is governed by van der Waals interactions, which affect body forces [16]. Increased surface area is the result of increases in crystalline substance size that are offset by morphological changes, flaws, and lattice contraction in crystallography. These modifications improve material solubility, which is essential for efficient drug delivery, by reducing crystallinity. The dynamics of nanodrug carriers within blood arteries are influenced by their size and shape. The significance of nanoparticle size in interactions with tumor blood capillaries is clarified by theoretical modeling. Another factor that influences nanoparticle behavior in vivo is shape. Transport, cell contact, and drug carrier pharmacokinetics are further influenced by variables such as size-to-shape ratio and edge geometry [17].

A key component of efficient medicine delivery is carrier material. In polymer-drug conjugates, the linker and polymer's chemical properties provide the drug specific features. Two crucial factors to consider are biocompatibility and biodegradability. Although biodegradability affects the length of drug release, material biocompatibility and inertness prevent harmful reactions with bodily tissues. Colloidal particle stability is influenced by charge, with surface charges being essential for long-term stability and interaction with biological materials. Surface characteristics are crucial to the function of nanoparticles because they have a substantial impact on stability, plasma dynamics, ligand attachment, and drug loading. Due to their huge surface area, nanoparticles are more prone to aggregation and thermal instability, which can affect their toxicity and performance. Agglomeration and disintegration, which are reversible and irreversible processes, have a substantial impact on the toxicity and efficacy of nanotherapeutics, underscoring the necessity of further research and mitigating measures. Agglomeration is primarily determined by concentration and size, which can be lessened via stabilizers and modifications to the dispersion medium [18].

Two approaches are used to approach nanosystems: top-down and bottom-up. By building nanoparticles from molecules, atoms, or macromolecules, the bottom-up method frequently makes use of solvents and precipitation techniques. On the other hand, the top-down strategy uses mechanical techniques like homogenization and milling to decrease big particles to nanoscale. When it comes to industrial drug nanoparticle production, top-down methods are most

common. Top-down techniques are preferred due to their scalability, even if bottom-up procedures produce nanoparticles with less surface flaws [19].

With active or passive targeting, nanodrug carriers provide specificity while lowering drug toxicity and increasing efficacy. Liposomal compositions minimize systemic toxicity by passively targeting tumors through increased retention and penetration effects. Passive tumor targeting is achieved by polymer-drug complexes. By altering their surface, nanotherapeutics can actively target certain disease locations and penetrate biological barriers. Because biological therapies are massive and unstable, they must be delivered via suitable carriers. Conjugates of polymers and proteins have proven to be effective transporters of different proteins. For targeted delivery to target areas, oligonucleotides such as siRNAs need carriers, which reduces off-target effects and increases therapeutic efficacy. It is necessary to take into account the distinct qualities of nanoparticle-based medicines in order to comprehend their pharmacokinetics. Nanotherapeutics have altered tissue distribution and extended drug release. Because of their prolonged absorption and accumulation in tissues, physiologically based pharmacokinetic (PBPK) models are not suitable for the therapeutic use of nanoparticles. Analyzing in vitro-in vivo correlations provides information on drug behavior in vivo and helps assess the stability, quality, and performance of nanoparticles [20].

In vitro-in vivo correlation studies provide time and cost-effective substitutes for biological equivalency studies in the development of oral formulations and quality control of nano-based therapies. Effective medication development and formulation optimization depend on the presence of both linear and nonlinear correlations between in vitro and in vivo responses [21-23].

Real Concerns About Nanotechnology-Based Drug Delivery:

Nanotechnology holds immense promise in revolutionizing healthcare by enabling novel drug delivery methods. While unconventional routes like oral delivery of insulin or inhalation present challenges, nanotechnology offers solutions by refining hydrophobic drugs to enhance solubility and bioavailability. Encapsulation of these drugs in nanoparticles using polymers and lipids can improve their ADME properties and reduce toxicity, leading to the production of first-generation nanoparticles. However, some studies suggest that nanotechnology may not always deliver the desired efficacy and could potentially introduce toxicity concerns, giving rise to the field of "nanotoxicology." Obtaining drug-loaded nanoparticles involves several essential steps, including solvent mixing, size reduction, solvent removal, and lyophilization of the drug-carrier complex.

Formulating drugs with nanotechnology-based carriers shifts the focus towards the chemical nature of the delivery vehicle rather than solely on the drug and disease treatment. This emphasizes the need to understand methods for improving drug delivery to the target site through various delivery systems, considering factors such as drug dose, route, and physicochemical properties of the ingredients involved.

Conclusion:

In conclusion, the exploration of nanotechnology in drug delivery systems represents a groundbreaking frontier in healthcare, offering transformative possibilities for therapeutic interventions. Throughout this discourse, we have delved into the multifaceted aspects of nanotechnology-based drug delivery systems, ranging from the fundamental principles of shape, size, and composition to the intricacies of surface characteristics, specificity, and pharmacokinetics. The significance of size and shape in nanoparticle design cannot be overstated, as these parameters profoundly influence cellular uptake, biodistribution, and pharmacokinetics. Moreover, the utilization of nanomaterials enables the manipulation of surface properties to enhance stability, target specificity, and interaction with biological molecules, thus optimizing drug delivery efficiency. Nanotechnology facilitates the delivery of therapeutic agents via various unconventional routes, addressing challenges associated with conventional administration methods. By encapsulating hydrophobic drugs in nanoparticles, nanotechnology enhances solubility, bioavailability, and therapeutic efficacy while mitigating toxicity concerns. However, as with any emerging technology, the adoption of nanotechnology in drug delivery also brings forth challenges and considerations, including potential toxicity issues and the need for comprehensive understanding and regulation in the field of nanotoxicology.

Despite these challenges, nanotechnology offers immense potential for revolutionizing drug delivery systems, paving the way for personalized medicine, targeted therapies, and improved patient outcomes. By refining drug delivery vehicles and focusing on the chemical nature of carriers, nanotechnology promises to usher in a new era of precision medicine, where treatments are tailored to individual patients and diseases. In essence, the future of healthcare lies at the intersection of nanotechnology and drug delivery, where innovative strategies and advanced materials converge to redefine the landscape of therapeutic interventions, offering hope for better treatments, enhanced patient care, and ultimately, improved quality of life.

References:

1. Bath, J., Tuberfield, A.J., 2007. DNA nanomachines. *Nat. Nanotechnol.* 2, 275284.
2. Maskos, M., Stauber, R.H., 2011. Characterization of nanoparticles in biological environments. In: Ducheyne, P., Healy, K.E., Hutmacher, D.W., Grainger, D.W., Kirkpatrick, C.J. (Eds.), *Comprehensive biomaterials*. Elsevier, pp. 329339
3. Torchilin, V.P., 2000. Drug targeting. *Eur J. Pharm. Sci.* 11, S81S91.
4. Mills, J.K., Needham, D., 1999. Targeted drug delivery. *Expert Opin. Ther. Patents.* 9, 1499 1513.
5. Bae, Y.H., Park, K., 2011. Targeted drug delivery to tumors: Myths, reality and possibility. *J. Control. Release.* 153, 198205
6. Lentacker, I., Vandenbroucke, R.E., Lucas, B., Demeester, J., De Smedt, S.C., Sanders, N.N., 2008. New strategies for nucleic acid delivery to conquer cellular and nuclear membranes. *J. Control. Release.* 132, 279288.

7. Jain, R.K., Stylianopoulos, T., 2010. Delivering nanomedicine to solid tumors. *Nat. Rev. Clin. Oncol.* 7, 653 664.
8. Sharma, N., Ojha, H., Bharadwaj, A., Pathak, D.P., Sharma, R.K., 2015. Preparation and catalytic applications of nanomaterials: A review. *RSC Adv.* 5, 53381 53403.
9. Wang, A.Z., Langer, R., Farokhzad, O.C., 2012. Nanoparticle delivery of cancer drugs. *Annu. Rev. Med.* 63, 185 198.
10. Li, M., Al-Jamal, K.T., Kostarelos, K., Reineke, J., 2010. Physiologically based pharmacokinetic modelling of nanoparticles. *ACS Nano* 4, 6303 6
11. Goldsmith, H.L., 1986. VTT Rheological aspects of thrombosis and hemostasis -basic principles and applications—Icth-Report—Subcommittee on Rheology of the International Committee on Thrombosis and Hemostasis. *Thromb. Haemost.* 55, 415 435
12. Duncan, R., 2003. The dawning era of polymer therapeutics. *Nat. Rev. Drug Discov.* 2, 347 361. Dunne, M., Corrigan, O.I., Ramtoola, Z., 2000. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. *Biomaterials.* 21, 1659 1668.
13. Gates, B.D., Xu, Q., Stewart, M., 2005. New approaches to nanofabrication: Molding, printing, and other techniques. *Chem. Rev.* 105, 1171 1196.
14. Liu, Y., Tan, J., Thomas, A., Ou-Yang, D., Muzykantov, V.R., 2012. The shape of things to come: Importance of design in nanotechnology for drug delivery. *Ther Deliv.* 3, 181 194
15. Liu, Z., Li, X., Xiu, B., Duan, C., Li, J., Zhang, X., et al., 2016. A novel and simple preparative method for uniform-sized PLGA microspheres: Preliminary application in anti tubercular drug delivery. *Colloids Surf. B Biointerfaces.* 145,
16. Auffan, M., Rose, J., Bottero, J.-Y., Lowry, G.V., Jolivet, J.-P., Wiesner, M.R., 2009. Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective. *Nat. Nanotechnol.* 4, 634 641.
17. Decuzzi, P., Ferrari, M., 2006. The adhesive strength of nonspherical particles mediated by specific interactions. *Biomaterials* 27, 53075314.
18. Devadasu, V.R., Bhardwaj, V., Kumar, M.N.V.R., 2013. Can controversial nanotechnology promise drug delivery. *Chem. Rev.* 113, A-AQ.
19. Hillyer, J.F., Albrecht, R.M., 2001. Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles. *J. Pharm. Sci.* 90, 19271936.
20. Gates, B.D., Xu, Q., Stewart, M., 2005. New approaches to nanofabrication: Molding, printing, and other techniques. *Chem. Rev.* 105, 11711196.
21. Murdock, R.C., Braydich-Stolle, L., Schrand, A.M., Schlager, J.J., Hussain, S.M., 2008. Characterization of nanomaterial dispersion in solution prior to in vitroexposure using dynamic light scattering technique. *Toxicol. Sci.* 101, 239253.
22. Parsons, G.E., Buckton, G., Chatham, S.M., 1992. The use of surface energy and polarity determinations to predict physical stability of nonpolar, nonaqueous suspensions. *Int. J. Pharm.* 83, 163170.

23. Van Eerdenbrugh, B., Van den Mooter, G., Augustijns, P., 2008. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. *Int. J. Pharm.* 364, 6475.